Bio Developments

© Getty Images

BenevolentAI progresses BEN-34712 for ALS treatment

By Isabel Cameron

BenevolentAI, a clinical-stage AI development company, has announced the successful delivery of its pre-clinical candidate for the potential treatment of amyotrophic lateral sclerosis (ALS), BEN-34712.

© Getty Images

Insmed unveils new research platforms and capabilities

By Isabel Cameron

US biopharma Insmed has announced progress across its early-stage research programs at the company's investor and analyst event, The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More.

© Getty Images

iOnctura reveals new translational cancer research

By Isabel Cameron

iOnctura, a clinical stage biotech company developing breakthrough therapies for cancer, has announced the peer-reviewed publication of translational research on the novel autotaxin (ATX) inhibitor IOA-289.


Genmab expands immunology reach in argenx pact

By Jonathan Smith

In a move to increase its presence in immunology and inflammation, the Danish biotech Genmab has launched a collaboration with argenx in the Netherlands to co-discover and co-develop antibody treatments.

Follow us


View more